ReviewInternational journal of burns and trauma2025
Meta-analysis of pregabalin combined with different methods for treating postherpetic neuralgia.
Review in International journal of burns and trauma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo conduct a meta-analysis of the literature on the treatment of postherpetic neuralgia (PHN) with pregabalin combined with different methods.
methodsSearch for relevant literature on the treatment of postherpetic neuralgia with pregabalin combined with different methods in both Chinese and English databases, including PubMed, Web of science, Cochrane Library, Wanfang Data, and China National Knowledge Infrastructure (CNKI).
resultsThe final inclusion consisted of 29 articles published between 2009 and 2023, with a total of 2,738 patients. Among them, 22 articles were RCTs, and 7 were non-RCTs. Seven articles reported on NRS, and the meta-analysis of continuous variable showed that the NRS scores in the study group were significantly lower than in the control group (OR = -1.05, 95% CI: -1.37 to -0.73, Z = -6.47, P < 0.01). Seven articles reported on breakthrough pain, and the meta-analysis of continuous variable showed that the frequency of breakthrough pain in the study group was significantly lower than in the control group (OR = -1.23, 95% CI: -1.52 to -0.94, Z = -8.31, P < 0.01). Five articles reported on SF-MPQ, and the meta-analysis of continuous variable showed that the SF-MPQ in the study group was significantly lower than in the control group (OR = -1.47, 95% CI: -2.14 to -0.81, Z = -4.33, P < 0.01). Ten articles reported on sleep quality, and the meta-analysis of continuous variable showed that the sleep quality scores in the study group were significantly lower than in the control group (OR = -2.16, 95% CI: -3.46 to -0.86, Z = -3.26, P < 0.01). Twenty articles reported on VAS, and the meta-analysis of continuous variable showed that the VAS scores in the study group were significantly lower than in the control group (OR = -1.17, 95% CI: -1.49 to -0.85, Z = -7.15, P < 0.01). Seven articles reported on efficacy, and the meta-analysis of dichotomous variable showed that the efficacy in the study group was significantly higher than in the control group (OR = 1.45, 95% CI: 0.94 to 1.95, Z = 5.65, P < 0.01). Thirteen articles reported on adverse reactions, and the meta-analysis of dichotomous variable showed no statistically significant difference in adverse reactions between the study and control groups (OR = 0.31, 95% CI: -0.01 to 0.62, Z = 1.92, P = 0.06). Ten articles reported on quality of life, and the meta-analysis of continuous variable showed that the quality of life scores in the study group were significantly higher than in the control group (OR = 1.00, 95% CI: 0.73 to 1.27, Z = 7.20, P < 0.01). Eleven articles reported on pregabalin dosage, and the meta-analysis of continuous variable showed that the dosage of pregabalin in the study group was significantly lower than in the control group (OR = -2.55, 95% CI: -3.15 to -1.95, Z = -8.30, P < 0.01). Funnel plot analysis indicated publication bias in VAS and pregabalin dosage but no publication bias in adverse reactions.
conclusionPregabalin combined with electroacupuncture, medications, pulsed radiofrequency, and nerve stimulation has shown good efficacy in the treatment of PHN and can be flexibly applied based on clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.